Compare Vaxcyte Inc. Common Stock (PCVX) vs Vivmark Residential Common Shares of Beneficial Interest (VMRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs Vivmark Residential Common Shares of Beneficial Interest — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while Vivmark Residential Common Shares of Beneficial Interest trades at $61.44 (market cap $47.36B). The key difference: Vivmark Residential Common Shares of Beneficial Interest is far larger — about 4.5× Vaxcyte Inc. Common Stock's market cap, and Vivmark Residential Common Shares of Beneficial Interest pays a 4.59% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Vivmark Residential Common Shares of Beneficial Interest for 6 Days on average.
| PCVX | VMRK | |
|---|---|---|
Market Cap | $10.51B | $47.36B |
Volume | 2,644,694 | 4,011,655 |
Sector | Health | Real Estate |
52-Week High | $73.82 | $70.15 |
52-Week Low | $40.32 | $57.98 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $9.14B | $56.46B |
Dividend Yield | — | 4.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VMRK trades at $61.2, down 0.08% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $3.04B and net income of $1.05B for 2025, but recent quarterly EPS misses and a slight decline in 2026 profit margins highlight near-term challenges. Recent news includes institutional buying and a credit rating upgrade to 'A' by S&P Global Ratings on August 18, 2026.
The outlook is mixed: analyst consensus is a buy with a $71.67 price target, but technical weakness and earnings misses pose risks. Opportunities include strong profitability and institutional support, while risks involve execution post-merger and market volatility. The stock's valuation metrics suggest it is fairly priced relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About Vivmark Residential Common Shares of Beneficial Interest
Vivmark Residential is a residential real estate investment trust that owns and operates apartment communities in U.S. markets. Its portfolio includes apartment homes and development projects.
Read more on VMRK →
